1. Home
  2. RAVE vs EVAX Comparison

RAVE vs EVAX Comparison

Compare RAVE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rave Restaurant Group Inc.

RAVE

Rave Restaurant Group Inc.

HOLD

Current Price

$2.94

Market Cap

39.1M

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$4.12

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAVE
EVAX
Founded
1958
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.1M
32.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
RAVE
EVAX
Price
$2.94
$4.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
90.2K
26.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
0.15
N/A
Revenue
$15,120,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
$19.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.25
$1.95
52 Week High
$3.75
$12.15

Technical Indicators

Market Signals
Indicator
RAVE
EVAX
Relative Strength Index (RSI) 59.95 49.28
Support Level $2.74 $3.96
Resistance Level $3.13 $4.65
Average True Range (ATR) 0.22 0.24
MACD 0.02 -0.04
Stochastic Oscillator 75.66 28.71

Price Performance

Historical Comparison
RAVE
EVAX

About RAVE Rave Restaurant Group Inc.

Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: